Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...

Comparing metagenomic profiles of the skin microbiome in immunosuppressed patients and those at high and low risk for cutaneous squamous cell carcinoma (SCC) revealed distinct expansions in fungal and ...

On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC) ...